company background image
6580 logo

TaiRx TPEX:6580 Stock Report

Last Price

NT$27.05

Market Cap

NT$3.0b

7D

0.2%

1Y

4.0%

Updated

23 Dec, 2024

Data

Company Financials

6580 Stock Overview

Focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. More details

6580 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

TaiRx, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for TaiRx
Historical stock prices
Current Share PriceNT$27.05
52 Week HighNT$44.00
52 Week LowNT$23.20
Beta0.70
1 Month Change-8.77%
3 Month Change-26.79%
1 Year Change4.04%
3 Year Change-45.85%
5 Year Change42.14%
Change since IPO-52.57%

Recent News & Updates

Recent updates

Companies Like TaiRx (GTSM:6580) Are In A Position To Invest In Growth

Mar 24
Companies Like TaiRx (GTSM:6580) Are In A Position To Invest In Growth

We Think TaiRx (GTSM:6580) Can Afford To Drive Business Growth

Dec 09
We Think TaiRx (GTSM:6580) Can Afford To Drive Business Growth

Shareholder Returns

6580TW BiotechsTW Market
7D0.2%-2.6%-2.1%
1Y4.0%-0.8%25.6%

Return vs Industry: 6580 exceeded the TW Biotechs industry which returned -0.8% over the past year.

Return vs Market: 6580 underperformed the TW Market which returned 25.6% over the past year.

Price Volatility

Is 6580's price volatile compared to industry and market?
6580 volatility
6580 Average Weekly Movement4.9%
Biotechs Industry Average Movement4.5%
Market Average Movement4.4%
10% most volatile stocks in TW Market7.8%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6580 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 6580's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011n/aDu-Shieng Chienwww.trx.com.tw

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis.

TaiRx, Inc. Fundamentals Summary

How do TaiRx's earnings and revenue compare to its market cap?
6580 fundamental statistics
Market capNT$2.97b
Earnings (TTM)-NT$183.76m
Revenue (TTM)NT$5.32m

562.2x

P/S Ratio

-16.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6580 income statement (TTM)
RevenueNT$5.32m
Cost of RevenueNT$3.65m
Gross ProfitNT$1.68m
Other ExpensesNT$185.44m
Earnings-NT$183.76m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.66
Gross Margin31.49%
Net Profit Margin-3,454.21%
Debt/Equity Ratio0%

How did 6580 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 15:59
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TaiRx, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution